Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
UBS
Dow
Teva
Fuji
AstraZeneca
Cipla
Medtronic
Mallinckrodt
Merck

Generated: October 24, 2017

DrugPatentWatch Database Preview

ASPIRIN Drug Profile

« Back to Dashboard

What is the patent landscape for Aspirin, and what generic Aspirin alternatives are available?

Aspirin is a drug marketed by Plx Pharma, Barr, Sandoz Inc, Par Pharm Inc, Zydus Pharms Usa Inc, Impax Labs Inc, and Amneal Pharms. and is included in seven NDAs. There are five patents protecting this drug.

This drug has thirty-two patent family members in eighteen countries and two supplementary protection certificates in two countries.

The generic ingredient in ASPIRIN is aspirin; dipyridamole. There are twenty-one drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the aspirin; dipyridamole profile page.

Summary for Tradename: ASPIRIN

US Patents:5
Applicants:7
NDAs:7
Bulk Api Vendors: see list73
Clinical Trials: see list1,125
Patent Applications: see list6,503
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ASPIRIN at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Plx Pharma
ASPIRIN
aspirin
CAPSULE;ORAL203697-001Jan 14, 2013OTCYesYes► Subscribe► Subscribe ► Subscribe
Plx Pharma
ASPIRIN
aspirin
CAPSULE;ORAL203697-001Jan 14, 2013OTCYesYes► Subscribe► SubscribeY ► Subscribe
Plx Pharma
ASPIRIN
aspirin
CAPSULE;ORAL203697-001Jan 14, 2013OTCYesYes► Subscribe► Subscribe ► Subscribe
Par Pharm Inc
ASPIRIN AND DIPYRIDAMOLE
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL207944-001Jan 18, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Plx Pharma
ASPIRIN
aspirin
CAPSULE;ORAL203697-001Jan 14, 2013OTCYesYes► Subscribe► SubscribeY ► Subscribe
Impax Labs Inc
ASPIRIN AND DIPYRIDAMOLE
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL206964-001Jan 18, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Barr
ASPIRIN AND DIPYRIDAMOLE
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL078804-001Aug 14, 2009ABRXNoNo► Subscribe► Subscribe► Subscribe
Amneal Pharms
ASPIRIN AND DIPYRIDAMOLE
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL206392-001Mar 8, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Zydus Pharms Usa Inc
ASPIRIN AND DIPYRIDAMOLE
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL206753-001Aug 29, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
ASPIRIN AND DIPYRIDAMOLE
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL206739-001Jan 18, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ASPIRIN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,911,752Methods of making compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity► Subscribe
9,730,884pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same► Subscribe
9,687,551Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ASPIRIN

Country Document Number Estimated Expiration
Canada2850187► Subscribe
Japan2005506303► Subscribe
China1543358► Subscribe
South Korea20140105436► Subscribe
South Korea20030072565► Subscribe
Austria414542► Subscribe
Germany60136647► Subscribe
Brazil0116380► Subscribe
Cyprus1110474► Subscribe
European Patent Office2760433► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ASPIRIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
12/048Ireland► SubscribePRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
2012000017Germany► SubscribePRODUCT NAME: ASPIRIN UND ESOMEPRAZOL - MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 81047.00.00 20110930 FIRST REGISTRATION: PORTUGAL 5402359 5402367 5402375 20110812
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Chubb
Argus Health
US Department of Justice
UBS
Express Scripts
Boehringer Ingelheim
Citi
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot